Last reviewed · How we verify
SCT650C
At a glance
| Generic name | SCT650C |
|---|---|
| Also known as | Recombinant anti-IL-17A antibody |
| Sponsor | Sinocelltech Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa (PHASE2)
- Efficacy and Safety of SCT650C in Participants With Axial Spondyloarthritis (PHASE2)
- Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SCT650C CI brief — competitive landscape report
- SCT650C updates RSS · CI watch RSS
- Sinocelltech Ltd. portfolio CI